Glucotrack director Paul V. Goode resigns citing potential conflict of interest

Glucotrack, Inc.

Paul V. Goode resigned from Glucotrack board effective Sept. 14, 2026.
Resignation cites potential conflict between company and subsidiary under Lokahi Therapeutics merger agreement.
Company provided resignation notice as Exhibit 17.1; Goode may file disagreement letter.
CEO Erik Emerson signed the 8-K; no replacement director named.
Conflict relates to implementing duties, rights, and obligations of entities in the merger.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Paul V. Goode

Director

GCTK · Glucotrack, Inc.

Effective: 2026-09-14
Filed: September 18, 2026, 5:10 PM ET

On September 14, 2026, Paul V. Goode notified the Board of Directors of Glucotrack, Inc. (the “Company”) of his resignation from the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Paul V. Goode resigned as Director at Glucotrack, Inc..

Action: resigned
Role: Director

Exact text from the filing

On September 14, 2026, Paul V. Goode notified the Board of Directors of Glucotrack, Inc. (the “Company”) of his resignation from the Board, effective immediately.

View on SEC.gov

Glucotrack, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-043389

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.